Amylyx Pharmaceuticals Inc
United States of America
Kent Leslie joined Amylyx Pharmaceuticals in 2015 and serves as Vice President of Research. Kent received his M.Sc in Biotechnology from Brown University while completing research in the lab of Dr. Richard Bennett. Prior to receiving his Master’s degree, Kent received Bachelor’s degrees in Biology and Economics from Brown University.
mylyx is developing a proprietary therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases that targets the neuroinflammation and nerve cell death that characterize these disorders. The company’s therapeutic, AMX0035, is a proprietary combination of existing compounds that Amylyx has demonstrated have synergistic effects in preventing nerve cell death and neurotoxic inflammation in multiple preclinical models.